CCND1 Antibody

CCND1

AI327039 antibody; B cell CLL/lymphoma 1 antibody; B cell leukemia 1 antibody; B cell lymphoma 1 protein antibody; B-cell lymphoma 1 protein antibody; BCL 1 antibody; BCL-1 antibody; BCL-1 oncogene antibody; BCL1 antibody; BCL1 oncogene antibody; ccnd1 antibody; CCND1/FSTL3 fusion gene antibody; CCND1/FSTL3 fusion gene; included antibody; CCND1/IGHG1 fusion gene antibody; CCND1/IGHG1 fusion gene; included antibody; CCND1/IGLC1 fusion gene antibody; CCND1/IGLC1 fusion gene; included antibody; CCND1/PTH fusion gene antibody; CCND1/PTH fusion gene; included antibody; CCND1_HUMAN antibody; cD1 antibody; Cyl 1 antibody; D11S287E antibody; G1/S specific cyclin D1 antibody; G1/S-specific cyclin-D1 antibody; Parathyroid adenomatosis 1 antibody; PRAD1 antibody; PRAD1 oncogene antibody; U21B31 antibody

A synthetic peptide of Human Cyclin D1

Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins. The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to effect progression through the restriction point and pRb-dependent entry into S-phase. The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression. Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of its protein expression and through phosphorylation-dependent degradation.

Affinity purification

Cell Biology

A synthetic peptide of Human Cyclin D1